Latest Hotspot

Silence Therapeutics Reports Positive 48-Week Phase 2 Results of Zerlasiran in Elevated Lipoprotein(a) Patients

26 June 2024
3 min read

Silence Therapeutics plc, Nasdaq: SLN, an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, announced positive topline 48-week data from the ALPACAR-360 phase 2 study of zerlasiran (SLN360) in 178 subjects with baseline lipoprotein, or Lp, levels at or over 125 nmol/L at high risk of atherosclerotic cardiovascular disease events.

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成Zerlasiran is a siRNA designed to lower the body’s production of Lp, a key genetic risk factor for cardiovascular disease affecting up to 20% of the world’s population.

In the double-blind placebo-controlled treatment period, zerlasiran was administered at 300 mg subcutaneously every 16 or 24 weeks and 450 mg every 24 weeks to patients with a median baseline Lp of approximately 215 nmol/L. These data demonstrated a highly significant reduction from baseline in Lp compared to placebo to 48 weeks. Median maximum Lp reduction of approximately 90% or greater was observed for both doses during the treatment period. 

Zerlasiran was well tolerated with no serious safety concerns. As previously announced, the study met its primary endpoint with a highly significant reduction from baseline in Lp compared to placebo to 36 weeks. The study is ongoing, and patients will be followed through to week 60.

“We are encouraged by the strength of the phase 2 data and emerging competitive profile of zerlasiran, which support an infrequent dosing regimen of at least quarterly with the 300 mg dose,” said Steven Romano, MD, Head of Research and Development at Silence. “We look forward to advancing zerlasiran to phase 3 as a potential treatment for this major unmet need in cardiovascular disease.”

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

According to the data provided by the Synapse Database, As of June 24, 2024, there are 11 investigational drugs for the lipoprotein(a) target, including 12 indications, 17 R&D institutions involved, with related clinical trials reaching 42, and as many as 4303 patents.

Zerlasiran targets lipoprotein(a), a known risk factor for cardiovascular diseases. As with any drug in clinical development, further research and testing are necessary to fully evaluate the safety and efficacy of Zerlasiran. However, its progression to Phase 2 trials indicates that it has shown promise in early studies, and its development is worth monitoring for potential future advancements in the treatment of cardiovascular diseases and related conditions. 

图形用户界面, 文本, 应用程序

描述已自动生成

Is Zanubrutinib approved by the FDA?
Drug Insights
3 min read
Is Zanubrutinib approved by the FDA?
26 June 2024
The U.S. Food and Drug Administration (FDA) approved Zanubrutinib on November 14, 2019.
Read →
Sarepta Therapeutics Gains Expanded FDA Approval for ELEVIDYS in Duchenne Muscular Dystrophy Patients Aged 4+
Latest Hotspot
3 min read
Sarepta Therapeutics Gains Expanded FDA Approval for ELEVIDYS in Duchenne Muscular Dystrophy Patients Aged 4+
26 June 2024
Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above.
Read →
Is Cefiderocol approved by the FDA?
Drug Insights
3 min read
Is Cefiderocol approved by the FDA?
26 June 2024
The U.S. Food and Drug Administration (FDA) approved Cefiderocol on November 14, 2019, for the treatment of complicated urinary tract infections (cUTIs) and hospital-acquired bacterial pneumonia (HABP), including ventilator-associated bacterial pneumonia (VABP).
Read →
Is Reblozyl approved by the FDA?
Drug Insights
4 min read
Is Reblozyl approved by the FDA?
26 June 2024
The U.S. Food and Drug Administration (FDA) approved Reblozyl on November 8, 2019, for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.